Tadalafil, a Phosphodiesterase-5 Inhibitor, Improves Erectile Dysfunction in Patients With Liver Cirrhosis.
CLD, Chronic Liver Disease
CTP, Child-Turcotte-Pugh
ED, Erectile Dysfunction
HE, Hepatic Encephalopathy
HRQOL, Health-Related Quality of Life
IIEF-15, International Index for Erectile Function
MELD, Model for End-Stage Liver Disease
MMSE, Mini-Mental State Examination
PDE, Phosphodiesterase
cirrhosis
erectile dysfunction
phosphodiesterase inhibitors
tadalafil
Journal
Journal of clinical and experimental hepatology
ISSN: 0973-6883
Titre abrégé: J Clin Exp Hepatol
Pays: India
ID NLM: 101574137
Informations de publication
Date de publication:
Historique:
received:
12
12
2017
accepted:
11
07
2018
entrez:
31
7
2019
pubmed:
31
7
2019
medline:
31
7
2019
Statut:
ppublish
Résumé
Erectile dysfunction(ED) is common in patients with chronic liver disease(CLD). Although it significantly worsens the quality of life, caregivers and researchers often neglect it. Evaluating the prevalence of ED in patients with CLD, associated factors, and response to therapy with tadalafil, a phosphodiesterase-5 inhibitor. A total of 60 males with Child-Pugh score between 5 and 10 and no overt hepatic encephalopathy were studied. ED was assessed based on the 15-question International Index of Erectile Function (IIEF) questionnaire. Patients were classified as ED+ if score was <25. Patients with ED were given 10 mg of tadalafil for 4 weeks. The mean age was 45.2 he 7.8 years. The mean Child-Turcotte-Pugh (CTP) score was 6.4 sc 1.7, and model for end-stage liver disease (MELD) score was 12.1 sc 4.5. Twenty-seven (45%) patients had compensated cirrhosis, and 45(75%) had alcohol as etiology. Twenty-five (42%) had an IIEF score <25, suggestive of ED. The IIEF score had significant correlation with the presence of ascites(r = -0.27, ED is common in patients with cirrhosis. Tadalafil administration significantly improves ED in these patients.
Sections du résumé
BACKGROUND
BACKGROUND
Erectile dysfunction(ED) is common in patients with chronic liver disease(CLD). Although it significantly worsens the quality of life, caregivers and researchers often neglect it.
AIM
OBJECTIVE
Evaluating the prevalence of ED in patients with CLD, associated factors, and response to therapy with tadalafil, a phosphodiesterase-5 inhibitor.
METHODS
METHODS
A total of 60 males with Child-Pugh score between 5 and 10 and no overt hepatic encephalopathy were studied. ED was assessed based on the 15-question International Index of Erectile Function (IIEF) questionnaire. Patients were classified as ED+ if score was <25. Patients with ED were given 10 mg of tadalafil for 4 weeks.
RESULTS
RESULTS
The mean age was 45.2 he 7.8 years. The mean Child-Turcotte-Pugh (CTP) score was 6.4 sc 1.7, and model for end-stage liver disease (MELD) score was 12.1 sc 4.5. Twenty-seven (45%) patients had compensated cirrhosis, and 45(75%) had alcohol as etiology. Twenty-five (42%) had an IIEF score <25, suggestive of ED. The IIEF score had significant correlation with the presence of ascites(r = -0.27,
CONCLUSION
CONCLUSIONS
ED is common in patients with cirrhosis. Tadalafil administration significantly improves ED in these patients.
Identifiants
pubmed: 31360023
doi: 10.1016/j.jceh.2018.07.007
pii: S0973-6883(18)30637-6
pmc: PMC6637079
doi:
Types de publication
Journal Article
Langues
eng
Pagination
312-317Références
J Urol. 2000 Feb;163(2):460-3
pubmed: 10647654
Am J Epidemiol. 2005 Feb 15;161(4):346-51
pubmed: 15692078
Int J Impot Res. 2005 Jul-Aug;17(4):343-5
pubmed: 15800652
J Gastroenterol. 2005 Sep;40(9):894-900
pubmed: 16211346
J Urol. 2006 Mar;175(3 Pt 1):1058-62
pubmed: 16469617
World J Gastroenterol. 2006 May 21;12(19):3073-6
pubmed: 16718790
Am J Gastroenterol. 2006 Jun;101(6):1235-43
pubmed: 16771944
Hepatogastroenterology. 1991 Dec;38(6):531-4
pubmed: 1778585
World J Gastroenterol. 2008 Oct 28;14(40):6208-12
pubmed: 18985812
J Sex Med. 2009 May;6(5):1395-401
pubmed: 19207273
Clin Gastroenterol Hepatol. 2010 Jun;8(6):546-9
pubmed: 20144739
J Sex Med. 2011 Dec;8(12):3316-24
pubmed: 21995779
J Sex Med. 2012 May;9(5):1295-302
pubmed: 22375942
PLoS One. 2013;8(4):e60443
pubmed: 23573257
Clin Mol Hepatol. 2015 Dec;21(4):352-7
pubmed: 26770923
JAMA. 1993 Jul 7;270(1):83-90
pubmed: 8510302
Urology. 1997 Jun;49(6):822-30
pubmed: 9187685